Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.
1. A method of decreasing white blood cell proliferation in a subject comprising the steps of:
(a) diagnosing the subject with one or more of respiratory distress syndrome, broncho-pulmonary dysplasia, pulmonary fibrosis and chronic obstructive pulmonary disorder;
(b) collecting a first blood sample;
(c) determining a white blood cell count for the first sample of blood;
(d) administering 1.5 mg to 5 mg rhCC10 per kg of subject body mass to a subject by the intratracheal, endotracheal, dialysate, ophthalmic, intravenous, systemic, or oral routes;
(e) collecting a second blood sample;
(f) determining a white blood cell count for the second sample of blood;
(g) observing a white blood cell count in the second blood sample which is at least 2% lower than the white blood cell count in the first blood sample.
2. The method of claim 1 wherein neutrophil levels are determined for the first and second blood samples and decreased by at least 2% after administration of rhCC10.
3. The method of claim 1 wherein polymorphonuclear leukocyte levels are determined for the first and second blood samples and decreased by at least 2% after administration of rhCC10.
4. A method of decreasing total cell counts in the tracheal aspirate fluids of a subject comprising the steps of:
(a) diagnosing the subject with one or more of respiratory distress syndrome, broncho-pulmonary dysplasia, pulmonary fibrosis and chronic obstructive pulmonary disorder;
(b) collecting a first sample of tracheal aspirate fluid;
(c) determining a total cell count for the first sample of tracheal aspirate fluid;
(d) administering 1.5 mg to 5 mg rhCC10 per kg of subject body mass to a subject by the intratracheal, endotracheal, dialysate, ophthalmic, intravenous, systemic, or oral routes;
(e) collecting a second sample of tracheal aspirate fluid;
(f) determining a total cell count for the second sample of tracheal aspirate fluid;
(g) observing a total cell count in the second sample of tracheal aspirate fluid which is at least 2% lower than the total cell count in the first sample of tracheal aspirate fluid.
5. The method of claim 4 wherein the subject reaches a peak combined tracheal aspirate fluid concentration of native CC10 and rhCC10 between about 12 and about 48 hours after initial dosage and wherein the combined concentration of native CC10 and rhCC10 is measured between about 12 and about 48 hours after initial dosage.
6. The method of claim 1 wherein the administration of rhCC10 is repeated about once every 48 hours.